Prof Karim Fizazi (Institut Gustave Roussy, Villejuif, France), Dr Anders Bjartell (Lund University, Lund, Sweden), Dr Niven Mehra (Radboud University Medical Center, Nijmegen, Netherlands) and Prof Eleni Efstathiou (Houston Methodist Cancer Center, Houston, USA) discuss best practice in HRRm testing in patients with metastatic prostate cancer.

The panel reviews guidelines related to testing patients for the presence of HRR mutations in metastatic prostate cancer. They also cover when to test for HRR mutations, including guideline recommendations on who should be tested.

Additionally, the panel addresses the implications of HRRm testing for both the patient and their family, as well as the available options for carrying out testing for this mutation. They also discuss the latest updates on PARP inhibitors for treating HRRm prostate cancer and understanding mutations in Homologous Recombination Repair genes in metastatic prostate cancer.

The panel concludes by discussing any relevant recent studies, including those from ESMO 2024.